A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2025-09-25
Target enrollment:
Participant gender:
Summary
The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum
acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary
efficacy of HS-10516 in ccRCC.